MedTrace Logo

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT06342960 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-10-29

No results posted yet for this study

Summary

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

Conditions

  • Lupus Nephritis
  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV

Interventions

BIOLOGICAL

KYV-101 anti-CD19 CAR-T cell therapy

KYV-101 anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

Sponsors & Collaborators

  • Kyverna Therapeutics

    lead INDUSTRY

Principal Investigators

  • MD · Kyverna Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2028-10-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06342960 on ClinicalTrials.gov